| ABSTRACT Objective:To evaluate systematically the clinical effectiveness and safety of Guanxinning injection (GXN) adjuvant conventional western treatment in treatment with unstable angina pectoris (UAP).Methods:Randomized controlled trials regarding UAP treated by GXN and western medicines (WM) were searched in the China National Knowledge Infrastructure Database, China Scienceand Technology Journal Database, Wanfang Database, Chinese Biomedical Literature Database, the Cochrane Library, Embase and PubMed. Two reviewers independently retrieved RCTs and extracted information. The Cochrane risk of bias method was used to assess the quality of included studies, and a Meta analysis was conducted with Review Manager 5.3 software. Results: 17 studies involving 1 517 participants were included. Meta analysis, the results of GXN group was significantly superior to the west conventional therapy group in angina pectoris curative effect (RR=1.24，95%CI: 1.18 1.30，P＜0.000 01), and the electrocardiogram curative effect (RR=1.34, 95%CI: 1.24 1.46, P<0.000 01). Additionally, GXN also could relieve angina frequency and traditional Chinese medicine (TCM) symptoms, reduce the dosage of nitroglycerin and myocardial oxygen consumption, slow heart rate, and so on. 8 articles cleared that there were no ADRs in the studies, 3 studies reported ADRs. There were 14 cases in the experimental group, and 14 cases in control group. Conclusion:Comparing with WM, the combine use of GXN was more effective, its safety was relatively safe. |
